Loading clinical trials...
Loading clinical trials...
Impact of Second Uterine Evacuation in Women With Non-metastatic, Low-risk Gestational Trophoblastic Neoplasia: A Phase III Trial
To evaluate the efficacy and safety of second uterine curettage in patients with low-risk non-metastatic GTN.
This is a randomized, multicenter clinical trial including patients seen at one of 13 gestational trophoblastic disease reference centers in Brazil. Subjects are eligible if they have low-risk gestational trophoblastic neoplasia according to FIGO 2000 criteria and the FIGO/WHO prognostic risk score. The study includes two treatment arms: immediate treatment with single-agent chemotherapy (center choice of agent) or second uterine curettage. The primary outcome is the rate of primary remission. Secondary outcomes are the number of chemotherapy cycles required to achieve remission, rate of primary chemotherapy resistance, rate of relapse, and overall survival.
Age
All ages
Sex
FEMALE
Healthy Volunteers
No
Paulista State University UNESP
Botucatu, Brazil
Campinas State University UNICAMP
Campinas, Brazil
University of Caxias do Sul
Caxias do Sul, Brazil
Federal University of Ceará
Ceará, Brazil
Medical School of Santa Casa da Misericórdia de Porto Alegre
Porto Alegre, Brazil
Maternidade Escola da Universidade Federal do Rio de Janeiro
Rio de Janeiro, Brazil
Federal University of São Paulo UNIFESP
São Paulo, Brazil
Start Date
February 11, 2021
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2025
Last Updated
May 27, 2022
150
ESTIMATED participants
Uterine curettage
PROCEDURE
Chemotherapy
DRUG
Lead Sponsor
Brigham and Women's Hospital
Collaborators
NCT05139095
NCT06169644
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03703271